Eupraxia Pharmaceuticals Inc. (TSX:EPRX)

Market Cap	191.08M
Revenue (ttm)	n/a
Net Income (ttm)	-38.30M
Shares Out	35.85M
EPS (ttm)	-1.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	104,300
Average Volume	48,241
Open	5.48
Previous Close	5.40
Day's Range	5.32 - 5.55
52-Week Range	3.07 - 6.49
Beta	1.52
RSI	58.77
Earnings Date	May 8, 2025

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company’s lead product candidates include EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and pain relief for knee osteoarthritis, and a product candidate intended for intra-articular use; PROMENADE, which is in a Phase III clinical trial of knee OA patients to evaluate the safety and efficacy of single and repeat doses of EP-104IAR...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 33
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: EPRX

Financial Performance

Financial numbers in USD